MLL: A histone methyltransferase disrupted in leukemia

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Rearrangements of the MLL gene, which is located at chromosome 11q23, are associated with aggressive acute leukemias in both children and adults. MLL regulates Hox gene expression through direct promoter binding and histone modification. MLL rearrangements occurring in leukemia include MLL fusion genes, partial tandem duplications of MLL and MLL amplification. MLL fusions and amplification upregulate Hox expression, apparently resulting in a block of hematopoietic differentiation. Future therapies for MLL-associated leukemia might involve blocking Hox gene upregulation by using fusion proteins or inhibiting the activity of Hox proteins themselves.

Original languageEnglish (US)
Pages (from-to)500-507
Number of pages8
JournalTrends in Molecular Medicine
Volume10
Issue number10
DOIs
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Leukemia
Homeobox Genes
Up-Regulation
Histone Code
Gene Rearrangement
Gene Fusion
Proteins
Chromosomes
Gene Expression
histone methyltransferase
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

MLL : A histone methyltransferase disrupted in leukemia. / Hess, Jay.

In: Trends in Molecular Medicine, Vol. 10, No. 10, 10.2004, p. 500-507.

Research output: Contribution to journalArticle

@article{c9d3d24d41d04dbb9c8cc0f6ac3b1656,
title = "MLL: A histone methyltransferase disrupted in leukemia",
abstract = "Rearrangements of the MLL gene, which is located at chromosome 11q23, are associated with aggressive acute leukemias in both children and adults. MLL regulates Hox gene expression through direct promoter binding and histone modification. MLL rearrangements occurring in leukemia include MLL fusion genes, partial tandem duplications of MLL and MLL amplification. MLL fusions and amplification upregulate Hox expression, apparently resulting in a block of hematopoietic differentiation. Future therapies for MLL-associated leukemia might involve blocking Hox gene upregulation by using fusion proteins or inhibiting the activity of Hox proteins themselves.",
author = "Jay Hess",
year = "2004",
month = "10",
doi = "10.1016/j.molmed.2004.08.005",
language = "English (US)",
volume = "10",
pages = "500--507",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - MLL

T2 - A histone methyltransferase disrupted in leukemia

AU - Hess, Jay

PY - 2004/10

Y1 - 2004/10

N2 - Rearrangements of the MLL gene, which is located at chromosome 11q23, are associated with aggressive acute leukemias in both children and adults. MLL regulates Hox gene expression through direct promoter binding and histone modification. MLL rearrangements occurring in leukemia include MLL fusion genes, partial tandem duplications of MLL and MLL amplification. MLL fusions and amplification upregulate Hox expression, apparently resulting in a block of hematopoietic differentiation. Future therapies for MLL-associated leukemia might involve blocking Hox gene upregulation by using fusion proteins or inhibiting the activity of Hox proteins themselves.

AB - Rearrangements of the MLL gene, which is located at chromosome 11q23, are associated with aggressive acute leukemias in both children and adults. MLL regulates Hox gene expression through direct promoter binding and histone modification. MLL rearrangements occurring in leukemia include MLL fusion genes, partial tandem duplications of MLL and MLL amplification. MLL fusions and amplification upregulate Hox expression, apparently resulting in a block of hematopoietic differentiation. Future therapies for MLL-associated leukemia might involve blocking Hox gene upregulation by using fusion proteins or inhibiting the activity of Hox proteins themselves.

UR - http://www.scopus.com/inward/record.url?scp=4644220954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644220954&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2004.08.005

DO - 10.1016/j.molmed.2004.08.005

M3 - Article

C2 - 15464450

AN - SCOPUS:4644220954

VL - 10

SP - 500

EP - 507

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 10

ER -